The offering provides near-term cash but dilutes existing holders by ~8-10%. Monitor for use-of-proceeds details and pipeline milestones (Huntington's, epilepsy, Fabry) that could offset dilution. The stock may face near-term pressure from the overhang of additional shares and potential selling by arbitrageurs post-close.
Price Chart
Executive Summary
uniQure priced an underwritten public offering of 4,945,055 ordinary shares at $45.50 per share, expecting approximately $225 million in gross proceeds. The offering includes a 30-day underwriter option for up to 741,758 additional shares. This dilutive capital raise provides cash runway for gene therapy pipeline programs (Huntington's, epilepsy, Fabry) but dilutes existing shareholders by roughly 10% based on the base offering.
Key Financial Metrics
Key Facts
- Priced 4,945,055 ordinary shares at $45.50 per share for ~$225M gross proceeds
- Underwriters have 30-day option to purchase up to 741,758 additional shares
- Offering expected to close on or about June 25, 2026
- Joint bookrunners: Leerink Partners, Stifel, Guggenheim Securities, RBC Capital Markets
- Lead manager: H.C. Wainwright & Co.
- Offered under automatically effective shelf registration statement on Form S-3 (File No. 333-284168)
Financial Impact
~$225M gross proceeds; dilution of ~10% from base offering (4.95M new shares vs. ~50M outstanding pre-offering, based on market cap of $2.8B and $45.50 price implying ~61.5M shares pre-offering, so ~8% dilution; plus up to 1.2% additional from over-allotment)
Risk Factors
- Dilution of ~8-10% from base offering; up to ~1.2% additional from over-allotment
- Potential near-term stock pressure from offering close and arbitrage selling
- Execution risk on pipeline programs; cash burn rate may require further financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3316560 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | 8-K | $46.23 $44.47 | ▼ −3.81% | ▼ −2.85% | $23.46 (−49.25%) |
Jul 29, 2026 9w ago | 8-K | $40.07 $44.24 | ▲ +10.41% | ▲ +4.88% | $23.46 (−41.45%) |
Jul 7, 2026 12w ago | Insider Cluster | $41.41 $41.52 | ▼ −0.27% | ▲ +0.29% | $23.46 (+43.35%) |
Jul 2, 2026 13w ago | Insider Cluster | $41.81 $44.48 | ▼ −6.39% | ▼ −5.46% | $23.46 (+43.89%) |
Jul 2, 2026 13w ago | Insider Cluster | $41.81 $44.48 | ▲ +6.39% | ▲ +5.46% | $23.46 (−43.89%) |
Jul 2, 2026 13w ago | 144 | $41.81 $44.48 | ▲ +6.39% | ▲ +5.46% | $23.46 (−43.89%) |
Jun 30, 2026 13w ago | 144 | $45.17 $41.41 | ▼ −8.32% | ▼ −8.59% | $23.46 (−48.06%) |
Jun 25, 2026 14w ago | 144 | $47.51 $41.81 | ▲ +12.00% | ▲ +14.16% | $23.46 (+50.62%) |
Jun 24, 2026 14w ago | 424B5 | $49.10 $45.17 | ▼ −8.00% | ▼ −9.56% | $23.46 (−52.22%) |
Jun 24, 2026 14w ago | 144 | $49.10 $45.17 | ▼ −8.00% | ▼ −9.56% | $23.46 (−52.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access